There is no pricing for a box of Puclumide, which is a new drug in the clinical trial phase. Androgen receptor antagonists are one of the preferred pharmacological treatments for controlling denervation-resistant prostate cancer at this stage, and Puclumide is a new generation of estrogen receptor antagonists for the treatment of denervation-resistant prostate cancer. The chemical structure of procurarumab has been altered in several ways compared to enzalutamide, resulting in improved molecular solubility and kinetics, avoiding overaccumulation of the drug, and thus potentially eliminating the CNS and other side effects that are clinically evident with enzalutamide. Phase III clinical trials on Puclumide are still underway, and the results of the clinical trials are the key to determining whether the drug can be marketed, so there is no clear pricing for this drug at home and abroad. It is recommended that patients consult professional doctors in regular hospitals, choose drug treatment under the guidance of doctors, and do not trust others to buy unauthorized drugs on the market.